FCRL2 Antibody
Description
Introduction to FCRL2 Antibody
FCRL2 Antibody refers to immunoglobulins designed to specifically bind Fc Receptor-Like 2 (FCRL2), a transmembrane glycoprotein expressed on B cells. FCRL2 is a member of the FCRL family, which regulates immune responses through immunoglobulin-like domains and cytoplasmic signaling motifs . These antibodies are critical tools for studying B-cell biology, chronic lymphocytic leukemia (CLL), and immune regulation.
Structure and Function of FCRL2
FCRL2 is a 382-amino acid protein with four extracellular immunoglobulin-like domains, a transmembrane segment, and intracellular signaling motifs (one ITAM-like, two ITIM-like) . Key features include:
-
Differential Expression: Preferentially expressed on naïve and CD27+ memory B cells in lymphoid tissues .
-
Signaling Regulation: ITIM motifs inhibit B-cell receptor (BCR) signaling by recruiting phosphatases like SHP-1, while ITAM-like motifs may modulate activation .
-
Clinical Relevance: Overexpression in mutated IGHV (M-CLL) correlates with favorable prognosis in CLL .
FCRL2 Antibody Types and Applications
Key Applications:
-
Flow Cytometry: Detects FCRL2 expression on B cells for distinguishing CLL subtypes .
-
Western Blot: Validates recombinant FCRL2 protein presence in cell lysates .
-
Prognostication: Monoclonal antibodies (e.g., 3E11) predict treatment-free survival in CLL .
Prognostic Value in Chronic Lymphocytic Leukemia (CLL)
FCRL2 expression strongly correlates with IGHV mutation status, a hallmark of indolent CLL .
-
Concordance: 94.4% alignment with IGHV mutation status vs. 76.6% for CD38 and 80.4% for ZAP-70 .
-
Survival Prediction: FCRL2-positive CLL patients show median treatment-free survival of 36.4 years vs. 5.26 years for FCRL2-negative cases .
Mechanistic Insights from Antibody Studies
-
BCR Signaling Inhibition: Anti-FCRL2 monoclonal antibodies (e.g., 5A7-E7, 3D8-G8) reduce calcium flux and MAPK phosphorylation, mimicking inhibitory signals .
-
ITIM Dependency: Tyrosine residues in ITIM motifs are essential for SHP-1 recruitment and signal suppression .
Clinical and Diagnostic Utility
| Parameter | FCRL2-Positive CLL | FCRL2-Negative CLL | Source |
|---|---|---|---|
| IGHV Mutation Status | Mutated (M-CLL) | Unmutated (U-CLL) | |
| Median Time to Treatment | 36.4 years | 5.26 years | |
| OS Prediction | Superior Prognosis | Poor Prognosis |
Diagnostic Advantages:
-
Simplified Workflow: PE-conjugated 3E11 enables one-step staining for clinical samples .
-
Stability: Concordance Correlation Coefficient (CCC) of 0.9 in repeated assays, ensuring reproducibility .
Challenges and Future Directions
Product Specs
Target Background
- Reduced FCRL4 expression and a correlation between FCRL2 expression and inflammatory markers and disease activity suggest that these molecules contribute to the inflammatory processes in rheumatoid arthritis. PMID: 27193470
- FCRL2 is overexpressed in B cells from patients with Hashimoto's and Graves' disease compared to healthy individuals. PMID: 25738996
- Studies indicate a negative immunomodulatory role for FCRL2 in the regulation of memory B cells. PMID: 21068405
- B-cell chronic lymphocytic leukemia (B-CLL) patients with high FCRL2 expression have significantly longer treatment-free survival and overall survival than those with low FCRL2 expression. PMID: 19682311
- FCRL2 has robust predictive value for determining IGHV gene mutation status and clinical progression in chronic lymphocytic leukemia, which may improve prognostic definition in this disease. PMID: 18314442
- Fc receptor-like 1-5 molecules are expressed similarly in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia. PMID: 18704934
- Down-regulation of FCRL2 is associated with acute lymphoblastic leukemia. PMID: 18802695
Show Less
